Who is the original manufacturer of Sotoraxibu? How much does it cost?
Sotorasib (Sotorasib), also known as AMG 510, is a highly specific targeted drug targeting the KRAS G12C gene mutation. It is mainly used to treat advanced or metastatic non-small cell lung cancer (NSCLC). Behind the development and production of this drug is Amgen, a well-known American biopharmaceutical company. As a leading global biotechnology company, Amgen has excellent R&D capabilities and a rich product line in the field of biopharmaceuticals. The successful launch of sotorasibu further consolidates its leading position in the field of cancer treatment.
The price of sotoraxibu varies depending on the version and origin. As a brand-name drug, the price of sotoraxib produced by Amgen is usually higher. For example, in Hong Kong , a box of 120mg*240 tablets of the original drug Sotolaxib sells for about 40,000 to 50,000 yuan. In addition, in countries such as Laos, generic versions of sotorasibu are also sold at more affordable prices. For example, the Lucius version sells for only about one to two thousand yuan per box, which greatly reduces the financial pressure on patients.
It should be noted that drug prices are affected by many factors, including production costs, tax policies, market demand, etc. Therefore, when purchasing sotoraxib, patients should choose the appropriate version and source based on their financial capabilities and treatment needs.
In addition, although sotoracib brings a new treatment option to NSCLC patients with KRAS G12C mutations, its efficacy may vary in different patients. Therefore, when using sotoracib for treatment, patients should follow the doctor's instructions, regularly monitor the treatment effects and adverse reactions, and adjust the treatment plan in a timely manner.
In short , the original manufacturer of sotorasibu is Amgen Pharmaceuticals in the United States. Its price varies depending on the version and place of origin. Patients should make choices based on their actual conditions when purchasing and using them, and follow doctor's instructions for standardized treatment.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)